If tirzepatide's dual-receptor mechanism represented a step change from semaglutide, retatrutide may represent a leap. Eli Lilly's triple-receptor agonist—targeting GIP, GLP-1, and glucagon receptors simultaneously—produced 24.2% mean body weight loss in a Phase 2 trial, the highest ever recorded for an anti-obesity medication.

24%+
Mean body weight loss in Phase 2 with retatrutide at the highest dose, surpassing tirzepatide (20%) and semaglutide (15%) in comparable timeframes.
Source: Jastreboff et al., NEJM 2023; Eli Lilly Phase 2 Data

The Triple-Receptor Mechanism

Where semaglutide activates one receptor (GLP-1) and tirzepatide activates two (GLP-1 + GIP), retatrutide activates three: GLP-1 + GIP + glucagon. The glucagon receptor activation is the key differentiator—it increases energy expenditure and promotes hepatic fat oxidation, addressing metabolic health beyond appetite suppression alone.

Phase 3 Status

Eli Lilly completed enrollment for the TRIUMPH phase 3 program in Q1 2026, with approximately 4,000 participants across three trials. Topline results are expected in Q4 2026, with an FDA filing anticipated in first-half 2027 if data are positive.

Sponsored · Teleios Health

Your GLP-1 Should Come With a Protocol

Labs, protein targets, resistance training, physician oversight. The complete system starting at $99/mo.

Start Your Program →

The Broader Pipeline

Retatrutide is not the only next-generation compound in development:

  • Survodutide (Boehringer Ingelheim): Dual GLP-1/glucagon agonist, Phase 3 for MASH and obesity
  • Pemvidutide (Altimmune): Another dual agonist showing promising Phase 2 data for liver fat reduction
  • Amycretin (Novo Nordisk): Dual GLP-1/amylin agonist with 13% weight loss at just 12 weeks in early data
  • CagriSema (Novo Nordisk): Semaglutide + cagrilintide combination showing enhanced efficacy over semaglutide alone

What This Means

We are entering an era where 20–25% body weight loss may become the standard expectation from pharmacotherapy. But efficacy amplification only intensifies the need for comprehensive clinical protocols. More weight loss means more muscle at risk, more micronutrient depletion, and more need for physician oversight.

Pipeline Watch

The next generation of obesity medications will be more effective than anything available today. Which makes the care gap even more dangerous. If patients are already losing 40% lean mass on current drugs, what happens when weight loss jumps to 25%? The protocol around the prescription has never mattered more.